SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.15), $0.05 worse than the analyst estimate of ($1.10).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Noodles & Company (NDLS) Tops Q2 EPS by 26c ; Offers Guidance
- Virginia National Bankshares Corporation. (VABK) Tops Q2 EPS by 165c
- Avidia Bancorp, Inc. (AVBC) Tops Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
